Streptomycin is an antibiotic medication used to treat a number of bacterial infections, including tuberculosis, Mycobacterium avium complex, endocarditis, brucellosis, Burkholderia infection, plague, tularemia, and rat bite fever. For active tuberculosis streptomycin is employed as an injectable bactericidal agent in combination regimens, typically reserved for specific cases such as drug intolerance, confirmed susceptibility, or part of multidrug regimens for retreatment and resistant strains; mechanistically streptomycin is an aminoglycoside that binds the 30S ribosomal subunit causing misreading of mRNA and inhibition of protein synthesis, it displays concentration dependent killing and post antibiotic effect, is poorly absorbed orally so administration is parenteral, is primarily renally excreted with a plasma half life in patients with normal renal function of approximately 2 to 5 hours, and requires therapeutic drug monitoring during prolonged therapy or renal impairment because of risks of irreversible cochleovestibular toxicity and nephrotoxicity and because resistance arises rapidly when used as monotherapy via ribosomal target mutations and aminoglycoside modifying enzymes.
Parent: Streptomycin/ Streptomycin Sulfate
Commercial streptomycin sulfate preparations and quality control monographs commonly define a controlled profile of related substances and degradation products; typical specification limits used in manufacturing and pharmacopeial guidance set total related substances not to exceed 2.0 percent by validated HPLC area percent, any single identified impurity generally limited to 1.0 percent, any single unidentified impurity limited to 0.5 percent, dihydrostreptomycin (a known degradation/impurity product) limited to 0.5 percent, streptomycin B and C related components each typically limited to 1.0 percent, streptidine and streptose traces expected at low ppm levels, heavy metals capped in the low parts per million range consistent with elemental impurity limits, and microbiological and residual solvent limits applied per regional regulatory expectations; manufacturers specify assay (potency) and impurity acceptance criteria in batch documentation and analytical methods such as HPLC and mass spectrometry are used to confirm these amounts.
Streptomycin is used to treat a range of serious bacterial infections including active tuberculosis as part of combination therapy, Mycobacterium avium complex in selected regimens, endocarditis when caused by susceptible organisms, brucellosis, Burkholderia infections, plague, tularemia, and rat bite fever; because it is bactericidal and concentration dependent it is used parenterally for systemic infections where those pathogens are proven or strongly suspected and when susceptibility data support its use.
Streptomycin is less commonly used in first line tuberculosis therapy today because of widespread resistance in many geographic regions, the availability of oral regimens that are more convenient and less toxic, the requirement for intramuscular administration, and the risk of ototoxicity and nephrotoxicity; it remains an option for specific indications such as confirmed susceptible isolates, intolerance to other agents, retreatment regimens, or certain drug resistant scenarios under specialist oversight with susceptibility testing and therapeutic monitoring.
Streptomycin does not cause infectious disease; the question likely refers to adverse effects which can be significant, the most notable streptomycin induced conditions are cochleovestibular toxicity presenting as irreversible hearing loss or balance dysfunction and nephrotoxicity manifesting as acute tubular injury; allergic reactions and neuromuscular blockade are less common but recognized adverse events.
No, streptomycin and penicillin are different antibiotic classes with distinct chemical structures, mechanisms, and spectra of activity; streptomycin is an aminoglycoside that inhibits bacterial protein synthesis at the 30S ribosomal subunit and requires parenteral dosing, while penicillin is a beta lactam that inhibits cell wall synthesis and is available in oral and parenteral forms; cross reactivity for allergic reactions is not expected because the two classes are structurally unrelated.
